Abstract：Objective: To study the efficacy of DWI and ADC in the treatment of breast cancer. Methods: From March 2014 to March 2016, we selected 45 cases of chemotherapy of breast cancer to analyze efficacy of MRI diagnosis. All of the patients underwent MRI examination before chemotherapy and after chemotherapy for three months, compared before and after chemotherapy on tumor size, ADC value, enhanced scanning of the sagittal and time-intensity curve(TIC) changes. Results: The size of tumor was (29.9±10.3) mm and the volume of (22 689.2±1 090.5) mm3 before chemotherapy and tumor size was (12.6±5.3) mm and volume of (15 042.9±211.2) mm3 after chemotherapy which had obvious difference(P<0.05). After chemotherapy in patients with ADCmean (1 102.6±102.3)×10-6 mm2/s and ADCmin (1 042.9±211.2)×10-6 mm2/s was significantly higher than that before chemotherapy (849.9±120.3) mm2 and (715.2±100.5) mm2/s, with statistical significance(P<0.05); before and after chemotherapy, the TIC type changed by the type Ⅲ to Ⅰ, and the difference was statistically significant(P<0.05). Conclusion: MRI evaluation after chemotherapy for breast cancer can reflect observe the changes of the lesions including ADC, and the trend of the change of TIC type Ⅲ to Ⅰ in patients after chemotherapy.
王 伟，于凤凯，韩云鹏，关 健. 磁共振弥散加权成像、表观扩散系数对乳腺癌化疗疗效的评价[J]. 中国临床医学影像杂志, 2018, 29(3): 161-164.
WANG Wei, YU Feng-kai, HAN Yun-peng, GUAN Jian. Evaluation of DWI, ADC on the efficacy of chemotherapy for breast cancer. JOURNAL OF CHINA MEDICAL IMAGING, 2018, 29(3): 161-164.
[1]夏碗君，王祥超，李功杰，等. 磁共振成像在乳腺癌新辅助化疗疗效评估中的应用[J]. 军事医学，2012，36（1）：56-59.
[2]杨露，毛伟明. MRI增强扫描与ADC序列观察肿瘤退缩率对乳腺癌化疗疗效的评估价值[J]. 中国CT和MRI杂志，2016，14（5）：62-65.
[3]Wu LM, Xu JR, Gu HY, et al. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better?[J]. J Surg Res, 2012, 178(1): 304-314.
[4]周礼金，李晓杰，纪婷，等. 磁共振动态增强VIEWS及弥散加权成像DWI在乳腺癌保乳术前评估的价值[J]. 中国CT和MRI杂志，2015，13（5）：74-76.
[5]Tsuchida T, Morikawa M, Demura Y, et al. Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxy glucose positron emission tomography and computed tomography[J]. J Magn Reson Imaging, 2013, 38(1): 80-88.
[6]姜蕾. 乳腺MRI评价乳腺癌新辅助化疗疗效中的应用[J]. 肿瘤影像学，2013，22（2）：151-154.
[7]王长河. 局部进展期乳腺癌新辅助化疗应用磁共振灌注成像的临床疗效研究[J]. 中国CT和MRI杂志，2015，13（2）：34-37.
[8]朱艳，陆洋，王娅婷，等. 表观扩散系数在乳腺癌肝转移早期疗效评价中的应用[J]. 临床放射学杂志，2015，34（7）：1097-1101.
[9]Weber MA, Bender K, von Gall CC, et al. Assessment of diffusion weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction[J]. J Gastr Liver Dis, 2013, 22(1): 45-52.
[10]王艳，权毅. MRI在乳腺癌新辅助化疗中的应用[J]. 现代临床医学，2016，42（1）：28-30.
[11]李富，曾健，李春燕，等. 磁共振成像表观扩散系数对乳腺癌新辅助化疗的疗效评估[J]. 中国现代医学杂志，2015，25（17）：66-69.
[12]胡丽霞，马捷，贾桂静，等. 磁共振在评价乳腺癌新辅助化疗疗效中的应用[J]. 黑龙江医学，2016，40（6）：523-525.
[13]Heijmen L, Verstappen MC, Ter Voert EE, et al. Tumor response prediction by diffusion-weighted MR imaging: ready for clinical use?[J]. Crit Rev Oncol Hematol, 2012, 83(2): 194-207.
[14]王卫理，丁勇俊，范晓芳. 磁共振弥散加权成像在乳腺癌新辅助化疗疗效监测中的应用价值[J]. 江苏医药，2013，39（11）：1314-1316.
[15]舒虹，段文峰，廖茜，等. MRI动态增强联合弥散加权诊断三阴性乳腺癌的临床研究[J]. 江西医药，2014，49（11）：1144-1146.
